IP Library › Granted Patent US 10,273,273
Granted Patent B2
US 10,273,273 · App. 15/651,988 · Granted Apr 30, 2019

Compositions for regulating iron homeostasis and methods of using same

Inventors: Herbert Y. Lin (Watertown, MA); Jodie L. Babitt (Newton Highlands, MA); Tracey Menhall (Boston, MA); Patrick Gearing (North Seattle, WA)
Assignees: THE GENERAL HOSPITAL CORPORATION; FERRUMAX CORPORATION
C07K14/4703C07K14/71C07K16/24C12N15/62A61K38/179C07K2319/21C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,273,273
App. No.
15/651,988
Granted
Apr 30, 2019
Kind
B2
Abstract

The present invention relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.

Claims (19)

1. A method of improving at least one symptom of a cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a composition comprising a fusion protein comprising the amino acid sequence of SEQ ID NO:9, thereby treating the cancer in the subject, and wherein the at least one symptom of a cancer is anemia.

2. The method of claim 1 , wherein the cancer is selected from the group consisting carcinoma, sarcoma, and lymphoma.

3. The method of claim 1 wherein the cancer is breast cancer.

4. The method of claim 1 , wherein the composition decreases metastasis of the cancer in the subject.

5. The method of claim 1 , wherein administration of the composition increases survival of the subject.

6. The method of claim 1 , wherein the subject has high levels of ferroportin.

7. The method of claim 1 , wherein the composition is administered in an amount sufficient to lower hepicidin gene expression in the subject.

8. The method of claim 1 , wherein administration is selected from the group consisting of intravenous, intramuscular, intraventricular, intrathecal injection, oral, topical, subcutaneous, subconjunctival, intranasal, intradermal, sublingual, vaginal, rectal and epidural routes.

9. The method of claim 1 , wherein administration is intravenous.

10. The method of claim 1 , wherein the composition is administered as part of a controlled release system.

11. The method of claim 1 , wherein the composition is associated with a polymer when administered to the subject.

12. The method of claim 1 , wherein 0.001 to 100 mg/kg of the composition is administered to the subject twice a week.

13. The method of claim 1 , wherein 10 to 30 mg/kg of the composition is administered to the subject twice a week.

14. The method of claim 1 , wherein 20 mg/kg of the composition is administered to the subject twice a week.

15. The method of claim 1 , wherein the subject is a human.

16. A method improving at least one symptom of breast cancer in a subject in need thereof by intravenously administering to the subject a therapeutically effective amount of a composition comprising a fusion protein comprising the amino acid sequence-of SEQ ID NO:9, thereby treating the breast cancer in the subject, and wherein the at least one improved symptom is anemia.

17. The method of claim 16 , wherein 0.001 to 100 mg/kg is administered to the subject are twice a week.

18. The method of claim 16 , wherein 10 to 30 mg/kg is administered to the subject twice a week.

19. The method of claim 15 , wherein 20 mg/kg of the composition is administered to the subject twice a week.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: GEARING, PATRICK; MENHALL, TRACEY
To: FERRUMAX CORPORATION
Reel/Frame 045815/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: LIN, HERBERT Y.; BABITT, JODIE L.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 045815/0457 →
Continuity (3)
Division 13980666
Provisional Application 61434405 · Jan 19, 2011
Related Publication 20180044389A1 · Feb 15, 2018
Cited By (5)
US 12,365,729 US 12,497,452 US 12,655,210 US 12,715,916 US 12,715,917